Hangzhou Tigermed Consulting Co., Ltd in 1 story
The narratives 3347.HK currently appears in, with its side and exposure in each.
Bull side
1 story- China Becomes Pharma's Global R&D Engine
3347.HK in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
As a leading Chinese clinical CRO, Tigermed benefits from rapid patient enrollment and growing demand for trials capable of supporting global regulatory submissions.
Bear side
0 storiesNo bear-side stories for 3347.HK yet.